- Home
- RNAC vs CGEN Comparison
RNAC vs CGEN Comparison
Compare RNAC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAC | CGEN |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.8M | 143.1M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RNAC | CGEN |
|---|---|---|
| Price | $6.68 | $1.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $38.40 | N/A |
| AVG Volume (30 Days) | 232.2K | ★ 397.7K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,091,000.00 | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.98 | $1.13 |
| 52 Week High | $20.12 | $2.66 |
Technical Indicators
Market Signals| Indicator | RNAC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 43.67 |
| Support Level | $6.40 | $1.47 |
| Resistance Level | $9.23 | $1.55 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 12.01 | 16.01 |
Price Performance
Historical ComparisonAbout RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.